title: Predictors of acid suppression success in patients with chronic laryngitis.
abstract: BACKGROUND
  Up to 50% of the patients suspected of reflux laryngitis syndrome failed to respond to acid suppression therapy. However, predictors of acid suppression success have not been determined.
  
  
  METHODS
  Consecutive patients with chronic laryngitis were enrolled prospectively. All the patients underwent laryngoscopy, esophagogastroduodenoscopy and 24-h multichannel intraluminal impedance and pH (MII-pH) monitoring before receiving rabeprazole 10 mg b.i.d. for 3 months. Patient was considered as a responder to acid suppression if the chief laryngeal complaint score during the last week since last interview had decreased by at least 50% after the start of therapy compared with baseline. Cox regression analysis was used to determine the independent predictors of acid suppression success.
  
  
  RESULTS
  Of 92 patients (age 42.4 ± 14.3 years, 50 women), 42 (45.7%) responded to acid suppression after 3 months. Gastroesophageal reflux disease was defined in 22 patients, of whom 19 patients had pathological distal esophageal acid exposure and 5 were defined as erosive esophagitis. The time to response showed a significant hazard ratio for patients with increased distal esophageal acid exposure time (β: 0.93; HR: 2.55; 95% CI: 1.24-5.24; P = 0.011) and increased laryngopharyngeal bolus exposure time (BET; β: 0.96; HR: 2.61; 95% CI: 1.36-5.00; P = 0.004). The latter had the best Youden Index (0.34) and accuracy (68.5%).
  
  
  CONCLUSIONS
  The success of acid suppression on chronic laryngitis could be predicted using reflux parameters detected by MII-pH, among which increased laryngopharyngeal BET is the best.
authors.affiliation: Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
authors.forename: A J
authors.initials: AJ
authors.lastname: Wang
authors.forename: M J
authors.initials: MJ
authors.lastname: Liang
authors.forename: A Y
authors.initials: AY
authors.lastname: Jiang
authors.forename: J K
authors.initials: JK
authors.lastname: Lin
authors.forename: Y L
authors.initials: YL
authors.lastname: Xiao
authors.forename: S
authors.initials: S
authors.lastname: Peng
authors.forename: J
authors.initials: J
authors.lastname: Chen
authors.forename: W P
authors.initials: WP
authors.lastname: Wen
authors.forename: M H
authors.initials: MH
authors.lastname: Chen
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D016145:Endoscopy, Digestive System; D049630:Esophageal Sphincter, Lower / Q000502:physiology; D050782:Esophageal pH Monitoring; D004947:Esophagus / Q000378:metabolism; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007827:Laryngitis / Q000188:drug therapy* / Q000209:etiology*; D057045:Laryngopharyngeal Reflux / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008365:Manometry; D008875:Middle Aged; D018670:Monitoring, Ambulatory; D011237:Predictive Value of Tests; D011379:Prognosis; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D064750:Rabeprazole; D012044:Regression Analysis; D055815:Young Adult
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D054328:Proton Pump Inhibitors; D064750:Rabeprazole